Dr. Hal S. Padgett co-founded Novici Biotech LLC in 2007. He and his team are focused on the development and use of new expression and host engineering tools to help plant-based systems meet their potential for producing high-quality recombinant proteins in a rapid and efficient manner.
Dr. Padgett received a B.S. in Life Sciences from the University of Missouri and earned a Ph.D. in Molecular Microbiology and Microbial Pathogenesis from Washington University in St. Louis while conducting his thesis research at The Scripps Research Institute in La Jolla. Prior to Novici, he served as Senior Scientist at Large Scale Biology Corporation where his duties included plant expression-system optimization and development of molecular breeding technologies for directed evolution. He currently serves on the Life Sciences Advisory Board to the California Biomanufacturing Center, a public/private effort focused on advancing biomanufacturing interests within the local and regional economy.
Dr. Padgett’s team at Novici has received funding over the years from the DOD for work with USAMRIID, the DOE-ARPA-E program for work with colleagues at LBNL, as well as grants from the NIH, and NSF. In the company’s purely commercial efforts, he and his team developed and launched, in 2009, the ErrASE technology for enzymatic DNA error correction in gene synthesis processes and have supplied this recombinant plant-made product to a significant portion of the synthetic biology market ever since. In response to constant pressures for higher-fidelity DNA products to fuel this market, the Novici team is preparing to launch its DirectASE product, a single-step post-synthesis enzymatic treatment that pushes fidelity well-beyond current benchmarks for commercial synthetic gene fragments.
Dr. Padgett has authored or coauthored 17 peer reviewed scientific articles and has 15 issued US Patents.